AbbVie invests in R&D for Chinese market
Print Edition
ABBVIE, a global biopharmaceutical firm, said the Chinese market is increasingly important and it will ensure its investment in research and development in its China division can cater to the domestic market.
“We are committed to the Chinese market,” said Scott Brun, vice president of AbbVie’s pharmaceutical development and research development, on a recent business trip in Shanghai.
“We will continue to expand our research team here, and increase the input in clinical development in particular, to get closer to Chinese patients.”
Last month, AbbVie officially established a Chinese team to drive development of pharmaceutical products to complement its research and development efforts.
AbbVie, a research-based pharmaceutical company focusing on drugs for rheumatoid arthritis, cancer, HIV, HCV and RSV infection, became independent in 2013 from health care firm Abbott.
In 2013, AbbVie set up its Chinese headquarters in Shanghai.
AbbVie has a number of clinical trials ongoing in China, including SONAR, a study evaluating a compound for use in slowing progression of diabetic kidney disease.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
